Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has launched ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The platform introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, ZetaOmics is designed to automate complex research workflows while embedding domain-specific intelligence intended to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. This capability could significantly reduce the time and effort required for bioinformatics tasks, enabling researchers to focus on interpreting results rather than managing data processing pipelines.
Lantern said the platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations. This move represents a new revenue stream for the company, as withZeta.ai is now commercially available as a subscription-based research platform for the global biomedical and drug development community.
The launch of ZetaOmics comes as part of Lantern’s broader strategy to leverage its proprietary RADR platform and artificial intelligence to transform the development of cancer therapies. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
For researchers and drug developers, ZetaOmics offers the potential to streamline bioinformatics analysis, reduce errors, and produce reproducible results. The autonomous nature of the platform could democratize access to advanced computational biology tools, enabling smaller institutions and companies to conduct sophisticated multi-omic analyses without requiring extensive in-house bioinformatics expertise. This could accelerate the pace of discovery in oncology and other disease areas.
Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. The company’s newsroom provides updates on its latest developments at https://ibn.fm/LTRN. The full press release about the ZetaOmics launch is available at https://ibn.fm/9sIIl.
As the pharmaceutical and biotechnology industries increasingly adopt AI-driven approaches, Lantern’s ZetaOmics platform could set a new standard for computational biology, potentially influencing how drug targets are identified and validated. The subscription-based model also signals a shift toward platform-as-a-service offerings in the life sciences, where companies can generate recurring revenue while enabling broader research capabilities.
